Skip to main content
Premium Trial:

Request an Annual Quote

Vizgen Launches With $14M Series A Financing

NEW YORK – Vizgen, a new startup in the spatial genomics field, said on Thursday that it has received $14 million in a Series A funding round led by Arch Venture Partners and Northpond Ventures.

In a statement, Cambridge, Massachusetts-based Vizgen said it would use the funds to accelerate commercialization of its patented "multiplexed error-robust fluorescence in situ hybridization" (MERFISH) platform. The technology enables spatially resolved, single-cell transcriptomics.

Xiaowei Zhuang, a Howard Hughes Medical Institute investigator, developed MERFISH in her lab at Harvard University with cofounder Jeffrey Moffitt, now a researcher at Boston Children's Hospital. Harvard's David Walt is also a cofounder and a member of the firm's board of directors.

"MERFISH is a game-changing technology in single-cell genomics and has broad applications in both fundamental biology and medicine," Walt, who also cofounded Illumina, Quanterix, and other firms, said in a statement. "Error detection and correction enable researchers to get the right answer. Vizgen's patented technology is critical for powering this unprecedented massively multiplexed single-molecule detection capability."

Northpond has recently participated in funding rounds for Inflammatix, IsoPlexis, Scipher, ChromaCode, SGI-DNA, SpeeDx, and Ultivue.

Arch Venture Partners also participated in Ultivue's Series C round. Over the last year, it also funded LunaPBC and One BioMed.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.